NCT02932566View on ClinicalTrials.gov

The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction

PHASE2CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

March 2, 2017

Primary Completion Date

November 29, 2019

Study Completion Date

April 29, 2020

Conditions
Cardiac Failure
Interventions
DRUG

Pirfenidone

Pirfenidone is an orally bioavailable, small molecule antifibrotic agent.

DRUG

Placebo

Placebo capsule, manufactured with the exact components of the Pirfenidone capsules, without the active ingredient / investigational medicinal product

Trial Locations (1)

M23 9LT

Manchester University NHS Foundation Trust, Manchester

All Listed Sponsors
collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

collaborator

University of Manchester

OTHER

collaborator

University of Liverpool

OTHER

collaborator

Hoffmann-La Roche

INDUSTRY

lead

Manchester University NHS Foundation Trust

OTHER_GOV

NCT02932566 - The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction | Biotech Hunter | Biotech Hunter